The US FDA has approved guselkumab for the treatment of moderate-to-severe plaque psoriasis and active psoriatic arthritis (PsA) in children aged 6 years or older who weigh at least 40 kg, according ...
Parents and policymakers face urgent questions about how new digital assistants influence kids’ wellbeing, a child services expert writes.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback